The global ablation technology market share is expected to grow at a CAGR of 9.54% during the forecast period (2021–2030).
Ablation technology is the process of removing part of biological tissue by surgery. Ablation devices offer a minimally invasive alternative to traditional surgeries for the treatment of prostate, kidney, liver, and lung cancer. The global ablation technology industry is segmented by products, application end-user, and regions. Due to the rising number of cancer and heart disease patients, it is an uprising market with great growth potential.
Chronic diseases such as cardiovascular diseases and cancer are major reasons for mortality. Inappropriate care and negligence in monitoring diseases have caused more demises. Statistics for Disease Control and Prevention Centers state that 18.2 million people of age 20 and above suffer from coronary artery disease. 6,55,000 people in the US die from heart diseases every year. According to the AHA of 2019, 5.3 million US citizens had atrial fibrillation.
The statistics of the British Heart Foundation Suggest that 7.4 million people in total including 3.9 million men and 3.5 million women have heart and circulatory diseases in the UK. The global cancer burden in 2018 was estimated to rise to 18.1 million new cases and 9.6 million worldwide deaths. To add to this, one in five men and one in six women are diagnosed with cancer. Asia-Pacific has the largest number of deaths due to cancer.
In 2016, the World Health Organization reported that 16.3% of the deaths in Asia-Pacific were due to cancer. Cardiovascular disease (CVD) is the second-largest disease that has haunted the Asia-Pacific region. Ablation is a minimally invasive procedure that includes surgical excision of body tissues. It has advantages such as the low risk of damaged tissues, reduced risk of infection, and speedy recovery. The ablation technology is also cost-effective, which is expected to boost ablation technology market growth.
In terms of cardiac arrhythmia, cancers, ophthalmologic and urological treatments, ablation technology has considerably advanced. These diseases are pretty disastrous as they have a history of severe symptoms. Some countries provide citizens with the facility of government medical insurance that covers hospital expenses, physician fees, equipment charges, etc.
The cost for the treatment differs with the severity and age of the patient. In India, it will cost around 1–1.25lakhs rupees to get catheter ablation. This cost may differ from the type of hospital, the surgeon, etc. In a decision-analytic model, Eckard et al estimated the cost for ablation to be around USD 58,000 per quality-adjusted life-year. This cost is predicted without assuming stroke prevention related to ablation strategy. Thus, the high cost can be a restraining factor for the global ablation technology market growth.
Countries including India, China, Malaysia, and South Korea are making critical advancements in terms of medical technology. These regions have seen a rise in geriatric patients, cancer, cardiovascular diseases, and liver disorders. This creates a great opportunity for the ablation technology to persevere. The large patient base in these countries creates potential opportunities.
In addition, growing healthcare expenditure, infrastructure, and low regulatory barriers are other bunch of reasons that have contributed to the ever-growing global ablation technology market share. Local and regional players in this market are majorly investing in R&D and this is expected to impact the market during the forecast period positively.
Ablation technology is a less invasive method to treat critical conditions such as different types of cancers and arrhythmias, cardiovascular diseases, etc. Products such as radiofrequency ablators, laser ablators, ultrasound ablators, electrical ablators, cryoablation devices, microwave ablators, and hydrothermal ablators are available in the global market and are used to treat serious diseases. Radiofrequency ablators are the most frequently used product and cover around 39% of the market. Due to its extensive use and newer applications, the demand for the product is forecasted to see a rise at a CAGR of 9.5% by the end of the year 2030.
The global ablation technology industry is becoming a booming sector due to its less invasive methods and growing patient base. It is used in cardiovascular disease treatment, cancer treatment, pain management and trauma, and others. Due to its effectiveness in the treatment, cancer patients are the major consumers of this technology. It roughly contributes 33% of the ablation technology market share and has been proven to be useful for lung, liver, and kidney cancer treatment.
Hospitals and surgical centers, ablation centers, ambulatory surgical centers, medical spas, aesthetic clinics, and others are the end-users of the ablation technology. Atrial fibrillations, cancer, chronic pain, and trauma among other critical conditions are the main reasons hospitals and surgical centers uphold this market by approximately 45%. Based on Straits research, this segment was valued at USD 15.24 million in 2020. By the end of 2030, the segment is expected to grow at a CAGR of 9.4%.
The pandemic has created huge havoc across the global medical network. In effect, the ablation technology and delivery care sector were hampered as well. People suffering from chronic ailments such as cancer, uterine fibroids, hemorrhagic stroke, etc. were affected the most. Pandemic restrictions had put limitations on surgical procedures, outpatient visits, etc. Selective and non-urgent procedures were put on halt.
If exposed to the virus, patients with cardiac arrhythmias and other respiratory disorders can experience complications, and thus, any procedure or visit that was avoidable was postponed or paused as well.
Ablation technology is widely used in regions such as Europe, Asia-Pacific, and the Middle East and Africa. Europe dominates the market with 60% and followed by Asia-Pacific and the Middle East and Africa at 31% and 8%, respectively. Europe had an evaluation of USD 1871.42 million in the year 2021 and has a growth potential of roughly 9.1%. The high amount of cancer and heart diseases prevailing in Europe are major driving factors for the market.
Germany and France have the biggest user base and roughly contribute to the European ablation technology market share by 31.1% and 24.1%, respectively. Here, radiofrequency ablators are the most used products for the prevailing cancer ailment across Europe. Whereas, CVD is responsible for 37% of mortalities in Europe.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|